0001209191-22-006835.txt : 20220203
0001209191-22-006835.hdr.sgml : 20220203
20220203164817
ACCESSION NUMBER: 0001209191-22-006835
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220201
FILED AS OF DATE: 20220203
DATE AS OF CHANGE: 20220203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Serbousek Jon Carl
CENTRAL INDEX KEY: 0001536875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19961
FILM NUMBER: 22589329
MAIL ADDRESS:
STREET 1: C/O BIOMET, INC.
STREET 2: P.O. BOX 587
CITY: WARSAW
STATE: IN
ZIP: 46581-0587
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Orthofix Medical Inc.
CENTRAL INDEX KEY: 0000884624
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3451 PLANO PARKWAY
CITY: LEWISVILLE
STATE: TX
ZIP: 75056
BUSINESS PHONE: 214-937-2000
MAIL ADDRESS:
STREET 1: 3451 PLANO PARKWAY
CITY: LEWISVILLE
STATE: TX
ZIP: 75056
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHOFIX INTERNATIONAL N V
DATE OF NAME CHANGE: 19970708
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-01
0
0000884624
Orthofix Medical Inc.
OFIX
0001536875
Serbousek Jon Carl
3451 PLANO PARKWAY
LEWISVILLE
TX
75056
1
1
0
0
CEO
Common Stock
2022-02-01
4
A
0
81967
0.00
A
194779
D
Performance Share Units
0.00
2022-02-01
4
A
0
81967
0.00
A
Common Stock
81967
81967
D
Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.
Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.
/s/ Kimberley A. Elting, Chief Legal and Development Officer, by power of attorney
2022-02-03